Alaunos Therapeutics, Inc. Operating Lease, Residual Value of Leased Asset
Alaunos Therapeutics, Inc. (TCRT) had Operating Lease, Residual Value of Leased Asset of $1.40 million as of 2021-12-31, per its 10-K filed 2023-03-07.
Discontinued › Notes › Leases
us-gaap:OperatingLeaseResidualValueOfLeasedAsset · last filed 2023-03-07
- 2021-12-31: Operating Lease, Residual Value of Leased Asset $1.40M.
| Period end | Operating Lease, Residual Value of Leased Asset |
|---|---|
| 2021-12-31 | $1.40M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |